← Sage — Cancer · Sage hub

Sage — Metabolic Hypothesis of mRNA Vaccine-Associated Cancer Relapse and Progression

Sage

Proteomic Load, Mitochondrial Insufficiency, and Warburg-like Reprogramming as Drivers of Immune Exhaustion and Oncogenic Rescue

Clinical observations from experienced oncologists, including Professor Angus Dalgleish, describe a concerning pattern: patients with long-term cancer remissions, sometimes lasting years, experiencing relapse or explosive progression shortly after receiving COVID-19 mRNA boosters. These “turbo” cancers have been reported as more aggressive, occurring in younger individuals than typical, and coinciding with repeated dosing. Dalgleish and others link this to T-cell exhaustion and impaired immune surveillance. While correlation does not equal causation, and SARS-CoV-2 infection itself carries metabolic and inflammatory sequelae, the temporal association with boosters and the consistency across multiple observers warrant a coherent mechanistic hypothesis rather than dismissal as coincidence or detection artifact [1]. Case-level reports and commentaries have described such temporal associations; whether they represent a causal signal remains unproven, and in a different direction SARS-CoV-2 mRNA vaccination has been shown to sensitize tumours to immune checkpoint blockade [2].

The dominant explanatory frame holds that mRNA vaccines are safe and effective, with serious adverse events rare and usually transient. Observed cancers are attributed to an aging population, improved diagnostics, direct effects of COVID-19, or random variation. Immune effects are viewed as expected, self-limited activation. This frame correctly notes the platform’s ability to generate antigen-specific responses and its role in reducing severe outcomes during the pandemic. Yet it leaves explanatory gaps precisely where cellular energy economy intersects with proteomic demand, toxicity repair, and sustained or repeated immune activation.

Where the Dominant Frame Falls Short

The prevailing view underweights the substantial bioenergetic cost imposed by the platform itself. Transfection of cells with mRNA directs ribosomal machinery toward large-scale translation of spike protein (and potentially aberrant products from frameshifting or contaminants) [4, 5]. Protein synthesis is among the most ATP- and GTP-intensive processes in the cell [3]. Each peptide bond formation, chaperone-assisted folding, trafficking, quality control, and eventual degradation or antigen processing consumes significant high-energy phosphates. When this load occurs across a wide tissue distribution—muscle, endothelium, antigen-presenting cells—the cumulative “engine load” on mitochondria can be substantial, especially with repeated dosing before full recovery of mitochondrial biogenesis, mitophagy, and respiratory chain capacity.

Spike protein has been reported to show pathogenic properties (“spikeopathy”), including endothelial disruption, complement activation, and inflammatory signaling that can generate reactive oxygen species capable of damaging mitochondrial membranes, mtDNA, and respiratory complexes [6, 7, 8]. Lipid nanoparticles add endosomal stress, innate immune activation, and oxidative burden [9, 10, 11]. The immune response mounted in response—clonal expansion, differentiation into effector and memory subsets, production of cytokines, antibodies, and cytotoxic molecules—is itself metabolically demanding. While acute immune activation often favors glycolysis for speed, sustained or repeated stimulation, particularly in the context of persistent antigen or chronic low-grade inflammation, can drive mitochondrial dysfunction and the exhausted phenotype characterized by upregulated checkpoints, reduced oxidative phosphorylation capacity, and impaired persistence and cytotoxicity [12, 13, 14, 15, 16].

A purely immunologic or genetic account struggles to explain why these effects would preferentially manifest as cancer relapse or aggressive new disease in some individuals but not others, why timing clusters after boosters, and why T-cell exhaustion—itself a metabolically defined state—appears central. It also fails to unify the observations with the broader epidemiology of metabolic comorbidities as cancer risk modifiers or with the known Warburg-like reprogramming that supports both rapid proliferation and immune dysfunction [17, 18, 21, 22].

The Metabolic Stressor Hypothesis

I propose that mRNA vaccination, particularly with repeated boosters, can function as an iatrogenic metabolic stressor that, in individuals with limited or already compromised mitochondrial reserve, creates a mismatch between ATP-generating capacity and acute or cumulative engine load. The primary drivers of this load are (1) the proteomic demand of spike protein translation and processing, (2) cellular repair and detoxification responses to spike- and adjuvant-related toxicity, and (3) the energetic cost of mounting and sustaining an adaptive immune response.

When oxidative phosphorylation cannot meet this demand—due to aging-related decline in mitochondrial biogenesis and quality control, prior insults (infections, toxins, chemotherapy, radiation), genetic or epigenetic vulnerabilities affecting respiratory chain efficiency, or coexisting insulin resistance and chronic inflammation—the cell or tissue may mount a primitive rescue program: upregulation of glycolysis and related pathways even in the presence of oxygen (a Warburg-like shift) [17, 18]. This ancestral fermentation program provides rapid ATP and carbon skeletons for biosynthesis at the expense of efficiency, generating lactate, altering redox balance, and reprogramming gene expression toward biomass production and survival under stress.

In immune effector cells, particularly CD8+ T-cells and NK cells, this metabolic reprogramming may contribute to the exhausted phenotype. Exhausted T-cells characteristically exhibit mitochondrial dysfunction, reduced spare respiratory capacity, reliance on glycolysis that becomes progressively impaired, and expression of inhibitory receptors [12, 13, 14, 15, 16]. On this hypothesis, repeated antigenic stimulation from boosters can mimic chronic antigen exposure, which may lock cells into this dysfunctional state and diminish tumor immune surveillance [20]. The result, on this hypothesis, is reduced capacity to recognize and eliminate occult residual disease or nascent transformed clones.

In precancerous or residual cancer cells, the same stressor or the resulting systemic milieu (inflammation, lactate signaling, possible compensatory hyperinsulinemia) may favor survival and selection of cells already operating near or beyond their mitochondrial limits. These cells may gain fitness advantage through enhanced glucose uptake, diversion of carbon into biosynthetic pathways, apoptosis resistance, and the ability to thrive in hypoxic or nutrient-variable microenvironments. Intratumoral Darwinian dynamics may then enrich for subclones optimized for glycolytic metabolism—the Warburg phenotype—accelerating progression and, on this hypothesis, producing the clinically observed aggressive behavior [17, 18, 19]. Prior cancer treatments may have already impaired mitochondrial reserve, lowering the threshold for this rescue-and-selection cascade upon subsequent metabolic stress.

Systemic effects may compound the process: chronic smoldering inflammation increases ROS burden on mitochondria across tissues; endothelial stress affects perfusion and oxygen delivery [6, 23]; and repeated hits without adequate recovery prevent restoration of mitochondrial flexibility. Individuals with higher baseline reserve—through genetic factors, younger age, optimized lifestyle, or absence of metabolic syndrome—may tolerate the load without crossing the threshold into clinically evident exhaustion or oncogenic acceleration. This accounts for variable susceptibility.

Reframing Key Phenotypes and Observations

This hypothesis reframes the Dalgleish pattern: long-term remission patients may relapse after boosters because immune surveillance, already metabolically fragile from prior disease and treatment, is further compromised by proteomic and inflammatory load driving T-cell exhaustion [1, 12, 14]. “Turbo” cancers in younger boosted individuals would, on this hypothesis, reflect rapid selection for carbon-optimized clones under conditions where mitochondrial insufficiency removes normal restraints on proliferation and survival. The predominance of certain aggressive histologies and unusual thrombotic features may reflect vascular and inflammatory components of spike toxicity acting on a metabolically stressed background [6, 7].

It also aligns with known biology: T-cell exhaustion has a well-documented metabolic signature involving mitochondrial impairment and glycolytic dysfunction [14, 15, 16]; cancer cells commonly exhibit some degree of Warburg reprogramming as a selected phenotype [17, 18, 19]; protein synthesis and immune activation are among the highest ATP-consuming processes [3]; and mitochondrial toxins or stressors can promote both genomic instability (via mtROS) and metabolic rescue.

Empirical Soundness, Convergent Mechanisms, and Falsifiability

Convergent lines support plausibility. Case reports and commentaries have described relapse and aggressive (“turbo”) cancer presentations temporally associated with boosters [1]; these do not by themselves establish causation, and counter-evidence includes work showing that SARS-CoV-2 mRNA vaccines can sensitize tumours to immune checkpoint blockade [2]. Laboratory work reports spike protein effects on endothelium, complement, and mitochondrial metabolism, including inflammatory amplification [6, 7, 8]. The bioenergetic cost of translation is fundamental biochemistry [3]. Metabolic reprogramming in exhausted T-cells and Warburg metabolism in cancer are extensively documented [14, 15, 16, 17, 18]. Epidemiological associations between metabolic comorbidities and cancer incidence or progression are well documented [21, 22]; links to poorer vaccine responses are less settled and are not claimed as established here.

The model is falsifiable. Prospective studies measuring mitochondrial biomarkers (e.g., respiratory chain function in peripheral blood mononuclear cells, mtDNA copy number or heteroplasmy, lactate/pyruvate ratios, or functional assays of spare respiratory capacity) before and after vaccination or boosting, correlated with subsequent T-cell phenotypes and cancer outcomes, would test core predictions. Serial metabolic imaging or single-cell profiling of tumors and immune infiltrates in patients receiving boosters could observe selection dynamics under metabolic stress. Randomized or observational data on mitochondrial-supportive interventions (nutrient density, circadian alignment, dynamic resistance training) as adjuncts in high-risk or recently vaccinated populations could quantify whether increasing engine reserve narrows risk. If the metabolic mismatch hypothesis holds, interventions that restore oxidative capacity or reduce unnecessary proteomic/inflammatory load should measurably improve immune competence and constrain oncogenic selection independent of or additive to conventional oncologic care.

Superior Parsimony and Comprehensiveness

A single upstream mechanism—bioenergetic insufficiency under proteomic and toxic load triggering Warburg-like glycolytic rescue—accounts, on this hypothesis, for both the immune exhaustion (T-cell dysfunction and loss of surveillance) and the oncogenic facilitation (selection for carbon-optimized clones) observed clinically. It integrates with the broader mitochondrial-metabolic hypothesis of cancer: mutations and hallmarks emerge and are selected within a pleiomorphic population already primed by energy crisis [19]. It unifies vaccine observations with other iatrogenic or environmental metabolic stressors and with the strong modifying effects of age, obesity, diabetes, and lifestyle on cancer risk and outcomes [21, 22]. It is more parsimonious than invoking separate, semi-independent processes for immune dysregulation, vascular injury, direct oncogenesis, and chance clustering. It supplies a coherent account of why repeated dosing may amplify risk in susceptible individuals and why recovery of mitochondrial function may be rate-limiting for resilience.

Therapeutic and Preventive Implications

If mitochondrial insufficiency and subsequent rescue-and-selection dynamics are central, prevention and mitigation begin with engine restoration and load management. This aligns with principles of mitochondrial optimization: prioritizing nutrient-dense whole foods supplying cofactors for respiratory chain and biogenesis; strategic moderation of refined carbohydrates and insulinogenic load to reduce competitive pressure on stressed mitochondria and limit carbon availability to glycolytic clones; circadian alignment to support quality control and hormonal rhythms; and dynamic resistance training to drive biogenesis, improve insulin sensitivity, and build functional metabolic reserve.

Conventional oncology (surgery, chemotherapy, radiation, targeted agents, immunotherapy) retains and likely gains value when deployed in a metabolically supported host. Mitochondrial optimization may protect normal tissues, bolster immune competence, and narrow the selective landscape favoring resistant or aggressive subclones. This is integrative and root-oriented, not oppositional: when cellular engines run closer to capacity and selective pressure for primitive rescue is reduced, conditions favoring both immune failure and malignant progression may diminish.

Conclusion

On this hypothesis, mRNA vaccination, especially repeated boosting, can act as a metabolic stressor whose proteomic, toxic, and immunologic demands exceed ATP-generating capacity in individuals with limited mitochondrial reserve. The resulting Warburg-like glycolytic rescue may promote T-cell exhaustion and loss of tumor surveillance while simultaneously creating selective conditions that accelerate progression of carbon-optimized neoplastic clones. This upstream reframing accounts for the observed patterns of post-booster relapse and turbo cancers more coherently than isolated immunologic or genetic accounts, integrates with established mechanisms of exhaustion and Warburg metabolism, and aligns with the broader mitochondrial-metabolic understanding of cancer as a disease enabled by energy-handling failure [12, 14, 17, 19].

It does not claim that every vaccinated individual will develop these outcomes—reserve, dose number, interval, and co-factors matter—nor does it negate the platform’s utility in defined contexts, including emerging evidence that SARS-CoV-2 mRNA vaccines can enhance responses to checkpoint blockade in some cancer settings [2]. It does argue that the bioenergetic dimension has been under-examined and that restoring and protecting mitochondrial engine function represents a high-leverage, modifiable strategy for increasing resilience to this and other metabolic stressors. When mechanistic depth, clinical signals, and interventional logic converge on root restoration alongside—not instead of—conventional care, medicine moves closer to genuine prevention and improved outcomes rather than perpetual management of downstream consequences.

This essay presents a hypothesis grounded in cellular bioenergetics, known mechanisms of protein synthesis cost, immune metabolism, spike pathogenicity, and intratumoral selection. It is not medical advice. Individual decisions regarding vaccination, boosting, or cancer care require personalized evaluation by a qualified physician integrating full clinical context, comorbidities, and current evidence. Open, rigorous investigation of these signals remains essential for scientific integrity and public trust.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised November 5, 2026.

References

mRNA vaccine-associated cancer relapse

  1. Kuperwasser C, El-Deiry WS. COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms. Oncotarget. 2026;17:1–29. doi:10.18632/oncotarget.28824. PMID 41498242.
  2. Grippin AJ, Marconi C, Copling S, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488–497. doi:10.1038/s41586-025-09655-y. PMID 41125896.
  3. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J. 1995;312(Pt 1):163–167. doi:10.1042/bj3120163. PMID 7492307.
  4. Mulroney TE, Pöyry T, Yam-Puc JC, et al. N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. Nature. 2024;625(7993):189–194. doi:10.1038/s41586-023-06800-3. PMID 38057663.
  5. Ogata AF, Cheng CA, Desjardins M, et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clin Infect Dis. 2022;74(4):715–718. doi:10.1093/cid/ciab465. PMID 34015087.
  6. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circ Res. 2021;128(9):1323–1326. doi:10.1161/CIRCRESAHA.121.318902. PMID 33784827.
  7. Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136(18):2080–2089. doi:10.1182/blood.2020008248. PMID 32877502.
  8. Zekri-Nechar K, Zamorano-León JJ, Reche C, et al. Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa. Oxid Med Cell Longev. 2022;2022:1118195. doi:10.1155/2022/1118195. PMID 36438904.
  9. Verbeke R, Hogan MJ, Loré K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55(11):1993–2005. doi:10.1016/j.immuni.2022.10.014. PMID 36351374.
  10. Ndeupen S, Qin Z, Jacobsen S, et al. The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021;24(12):103479. doi:10.1016/j.isci.2021.103479. PMID 34841223.
  11. Tahtinen S, Tong AJ, Himmels P, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532–542. doi:10.1038/s41590-022-01160-y. PMID 35332327.
  12. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862. PMID 26205583.
  13. Blank CU, Haining WN, Held W, et al. Defining 'T cell exhaustion'. Nat Rev Immunol. 2019;19(11):665–674. doi:10.1038/s41577-019-0221-9. PMID 31570879.
  14. Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity. 2016;45(2):358–373. doi:10.1016/j.immuni.2016.07.008. PMID 27496729.
  15. Scharping NE, Rivadeneira DB, Menk AV, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205–215. doi:10.1038/s41590-020-00834-9. PMID 33398183.
  16. Yu YR, Imrichova H, Wang H, et al. Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion. Nat Immunol. 2020;21(12):1540–1551. doi:10.1038/s41590-020-0793-3. PMID 33020660.
  17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809. PMID 19460998.
  18. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211–218. doi:10.1016/j.tibs.2015.12.001. PMID 26778478.
  19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013. PMID 21376230.
  20. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329–360. doi:10.1146/annurev.immunol.22.012703.104803. PMID 15032581.
  21. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. doi:10.1056/NEJMoa021423. PMID 12711737.
  22. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602. PMID 27557308.
  23. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5. PMID 32325026.

Related: Sage — Cancer (Oncology chapter) · Sage — Immune · Sage — Warburg and Crabtree

See the notice at the top of this page. Working hypothesis, not medical advice.